

Press release

Amoéba announces the publication of its Universal Registration Document 2024

Chassieu (France), 17 April 2025 – 6 p.m. - Amoéba (FR0011051598 - ALMIB), an industrial greentech specialized in the development of natural microbiological solutions based on the patented use of amoebae, announces that it has made available to the public and filed with the French Financial Markets Authority (Autorité des Marchés Financiers (AMF)) today its 2024 Universal Registration Document, under number D.25-0281.

The Universal Registration Document 2024, for the financial year ending 31 December 2024, includes in particular:

- The 2024 annual financial report, consisting of the consolidated financial statements, the annual financial statements, the management report and the related statutory auditors' reports;
- The report on corporate governance drawn up by the Board of Directors.

The Universal Registration Document 2024 can be consulted on the company's website at the following address <https://amoeba-nature.com/> in the "Investor" / "Financial documents" / "2024 Universal Registration Document" section.

About Amoéba:

Founded in 2010, Amoéba is a greentech company based in Chassieu (Lyon, France) whose ambition is to become a major player in the treatment of microbiological risk based on the patented use of amoebae in the plant protection and cosmetics sectors.

With know-how that is unique in the world and protected by numerous patents, Amoéba is currently the only company capable of exploiting the full potential of the *Willaertia* amoeba on an industrial scale and growing it in sufficient volumes to offer biological solutions that constitute a viable alternative to the chemical products widely used today. Amoéba is currently focusing on the global biocontrol market for plant protection and the cosmetics market. As the marketing of plant protection products is subject to obtaining local regulatory approvals, the Company has taken the necessary regulatory steps and in 2022 obtained approval for its active substance in the USA as well as the recommendation for approval in Europe issued by the Austrian authority. Cosmetic applications do not require prior approval from a competent authority in Europe or the United States.

Amoéba is listed on Euronext Growth (ALMIB). The company is a member of the Bpifrance Excellence network and is eligible for the PEA-PME scheme. For more information, visit www.amoeba-nature.com.

Contacts:

Amoéba	ACTUS finance & communication	Droit Devant Agency	
<i>Chief Executive Officer</i> Jean-François DOUCET  +33 (0)4 26 69 16 00  jf.doucet@amoeba-nature.com	<i>Investor relations</i> Pierre JACQUEMIN-GUILLAUME  +33 (0)1 53 67 36 79  amoeba@actus.fr	<i>Financial press relations</i> Serena BONI  +33 (0)4 72 18 04 92  sboni@actus.fr	<i>Business and general public press relations</i> Laëtitia PINTO  +33 (0)7 64 83 39 85  pinto@droitdevant.fr

Disclaimer

This press release contains certain forward-looking statements concerning Amoéba which are based on its own assumptions and estimates and on information that is currently available to us. However, Amoéba gives no assurance that the estimates contained in such forward-looking statements will be verified, with these estimates subject to numerous risks, including the risks set forth in Amoéba's universal registration document filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 17, 2025 under number D.25-0281 and available on the Amoéba website (www.amoeba-nature.com). The forward-looking statements contained in this press release are also subject to risks not yet known to Amoéba or not currently considered material by Amoéba. The occurrence of all or part of such risks could cause Amoéba's actual results, financial conditions, performance, or achievements to be materially different from such forward-looking statements.